Clinical trial · Interventional
The Effect of Esketamine on Patients Undergoing Tumor Surgery
Effects of Esketamine on Postoperative Pain, Anxiety and Depression in Patients Undergoing Tumor Surgery
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Although the acute and chronic postoperative pain of surgical patients has gradually been paid attention to, it has not yet been better resolved.and, the incidence of anxiety and depression in cancer patients is constantly increasing，The new analgesic anesthetic esketamine hydrochloride was launched in China last year，however, in the domestic and foreign literature, there are still few reports of esketamine hydrochloride in postoperative analgesia, and most of them are retrospective and small samples.This study aims to investigate whether esketamine has advantages over traditional opioids in terms of postoperative analgesia, anxiety and depression in cancer patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Tumor Surgery | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| High-dose Esketamine hydrochloride+Hydromorphone | Drug | — | UNRESOLVED |
| Hydromorphone | Drug | — | UNRESOLVED |
| Low-dose Esketamine hydrochloride+Hydromorphone | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- High-dose esketamine group
- description
- After the operation, 5 mg esketamine was injected intravenously for postoperative analgesia. PCIA formula: hydromorphone 6mg + esketamine 45mg + tropisetron 10mg into 0.9% sodium chloride injection 100ml, the first dose is 20ug/kg , Background dose 2ug/kg/h, single dose 4ug/kg/time
- interventionNames
- Drug: High-dose Esketamine hydrochloride+Hydromorphone
- type
- EXPERIMENTAL
- label
- Low-dose esketamine group
- description
- After the operation, esketamine 2.5mg was injected intravenously for postoperative analgesia. PCIA formula: hydromorphone 6mg + esketamine 22.5mg + tropisetron 10mg into 0.9% sodium chloride injection 100ml, the first dose is 20ug/ kg, background dose 2ug/kg/h, single dose 4ug/kg/time
- interventionNames
- Drug: Low-dose Esketamine hydrochloride+Hydromorphone
- type
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥18 years old; * Patients undergoing elective tumor surgery * Use intravenous analgesia pump (PCIA) after operation Exclusion Criteria: * Patients with severe infection or respiratory system diseases; * Severe arrhythmia, unstable angina or myocardial infarction, heart failure; * Patients with severe diseases of liver, kidney, endocrine or immune system; ·Patients with fever before operation; * One month before operation Patients receiving chemotherapy, radiotherapy or immunotherapy; * Drug or alcohol dependence; * Mental illness, disturbance of consciousness and communication difficulties or inability to understand the questionnaire or refusal to complete; * Long-term use of antidepressant and anxiety drugs; * High intracranial pressure High intraocular pressure
References
Publications (0)
Data not yet available